Prostate Cancer Screening Liverpool NY
Prostate cancer screening consists of diagnostic tests that can assist with early detection of prostate cancer. Screening may involve a digital rectal exam, prostate-sspecific antigen (PSA) blood test, or a transrectal ultrasound. See below to learn more and to gain access to qualified oncologists in Liverpool, NY who provide prostate cancer screening.
Manuel G Dalope, MD
315-474-4475
5116 West Tatt Road
Liverpool, NY
Manuel G Dalope, MD
315-474-4475
5116 West Tatt Road
Liverpool, NY 13088
Specialties
Oncology (Cancer), Radiation Oncology
Education
Medical School: Univ Of The Philippines, Coll Of Med, Manila, Philippines
Graduation Year: 1970
Data Provided by:
Nabila Adham Elbadawi, MD
315-474-4475
815 James St
Syracuse, NY
Nabila Adham Elbadawi, MD
315-474-4475
815 James St
Syracuse, NY 13203
Specialties
Oncology (Cancer), Radiation Oncology
Education
Medical School: Kasr El Aini Fac Med Cairo Univ, Cairo (915-02 After 1/1971)
Graduation Year: 1960
Data Provided by:
Peter David Sadowitz, MD
315-488-9162
2731 W Foxhill Ln
Camillus, NY
Peter David Sadowitz, MD
315-488-9162
2731 W Foxhill Ln
Camillus, NY 13031
Specialties
Oncology (Cancer)
Education
Medical School: Suny-Hlth Sci Ctr At Syracuse, Coll Of Med, Syracuse Ny 13210
Graduation Year: 1979
Data Provided by:
Keith D Goldstein, MD
315-464-8200
750 E Adams St
Syracuse, NY
Keith D Goldstein, MD
315-464-8200
750 E Adams St
Syracuse, NY 13210
Specialties
Oncology (Cancer)
Education
Graduation Year: 2007
Data Provided by:
Seung Shin Hahn
(315) 464-5276
750 E Adams St
Syracuse, NY
(315) 464-5276
750 E Adams St
Syracuse, NY 13210
Specialty
Radiation Oncology
Data Provided by:
Abdul Ghaffar Musa, MD
315-423-0208
101 S Warren St
Syracuse, NY
Abdul Ghaffar Musa, MD
315-423-0208
101 S Warren St
Syracuse, NY 13202
Specialties
Oncology (Cancer)
Education
Medical School: American Univ Of Beirut, Fac Of Med, Beirut, Lebanon
Graduation Year: 1966
Data Provided by:
Kin Yui Lam, MD
212-941-9020
50 Presidential Plz Apt 601
Syracuse, NY
Kin Yui Lam, MD
212-941-9020
50 Presidential Plz Apt 601
Syracuse, NY 13202
Specialties
Internal Medicine, Hematology-Oncology
Education
Medical School: Univ Of Hong Kong, Fac Of Med, Hong Kong
Graduation Year: 1983
Hospital
Hospital: St Vincents Hospital, New York, Ny
Data Provided by:
Sara Jo Grethlein, MD
315-464-8200
750 E Adams St
Syracuse, NY
Sara Jo Grethlein, MD
315-464-8200
750 E Adams St
Syracuse, NY 13210
Specialties
Oncology (Cancer)
Education
Graduation Year: 2007
Data Provided by:
Michael Meguid, MD
315-464-6277
750 E Adams St
Syracuse, NY
Michael Meguid, MD
315-464-6277
750 E Adams St
Syracuse, NY 13210
Specialties
Oncology (Cancer)
Education
Medical School: Univ Of London, Univ Coll, Sch Of Med (See 917-34)
Graduation Year: 1968
Data Provided by:
Jeffrey Alan Bogart, MD
315-464-5276
750 E Adams St
Syracuse, NY
Jeffrey Alan Bogart, MD
315-464-5276
750 E Adams St
Syracuse, NY 13210
Specialties
Oncology (Cancer), Radiation Oncology
Education
Medical School: Suny-Hlth Sci Ctr At Syracuse, Coll Of Med, Syracuse Ny 13210
Graduation Year: 1989
Data Provided by:
Data Provided by:
The PSA (Prostate-Specific Antigen) test is one of two primary screening tools for prostate cancer. This simple blood test measures the level of PSA, a protein produced in the prostate, present in a man's body. Men typically have an initial PSA screening at 50, or earlier if there's a family history of prostate cancer.
Physicians measure PSA in nanograms per milliliter. An elevated PSA doesn't diagnose cancer and doesn't mean a man has prostate cancer; it just suggests further evaluation. Other medical conditions can also raise PSA levels. A PSA test and additional diagnostic tools help detect small tumors, however, experts say it does not necessarily reduce a man's chance of dying of prostate cancer.
An increase in PSA is the strongest single predictor of prostate cancer risk, and a high PSA score followed by a lower PSA score is not uncommon, even in men who do have cancer. However, PSA progression does predict poor overall survival rates in men with mestacized prostate cancer (meaning it has spread beyond the prostate). The PSA test is actually a better predictor of prostate cancer risk in African-American men with family histories compared to European- American men.
There is controversy over the value of PSA screenings. This spring, researchers released the results of a large-scale study that began in 1992 to evaluate whether or not the PSA test benefited men. In the subsequent media coverage of the results, the news varied widely depending on who was doing the reporting...
Click here to read more from Quality Health